Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.22 USD
-0.07 (-0.62%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $11.22 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.22 USD
-0.07 (-0.62%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $11.22 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
by Zacks Equity Research
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 100% and 4.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara (CERT) delivered earnings and revenue surprises of -36.36% and 1.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clene (CLNN) delivered earnings and revenue surprises of 0% and 54.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -83.33% and 0.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
by Zacks Equity Research
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
by Zacks Equity Research
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.